Regulatory News:
Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account as of June 30, 2026:
- Number of shares: 118,866 shares
- Cash balance: €96,894.38
During the first half of 2026, a total of:
PURCHASES | 282,460 shares | €933,897.51 | 361 transactions |
SALE | 226,618 securities | €782,823.64 | 283 transactions |
It should be noted that as of the half-yearly balance sheet dated December 31, 2025, the following assets were recorded in the cash account:
- Number of shares: 63,024 shares
- Cash balance: €257,777.69
It is noted that upon the establishment of the liquidity agreement, the following assets were made available:
- Number of shares: 131,000 shares
- Cash balance: €40,801.20
APPENDIX H1 2026
Purchases | Sales | |||||
ABNX FP | Number of Transactions | Number of Securities | Capital in EUR | Number of Transactions | Number of securities | Capital in EUR |
Total | 361 | 282,460 | 933,897.51 | 283 | 226,618 | 783,823.64 |
20260101 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260102 | 1 | 1 | 3.86 | 6 | 6,971 | 27,579.56 |
20260105 | 5 | 7,061 | 26,946.26 | 1 | 1 | 3.96 |
20260106 | 2 | 2,051 | 7,527.21 | 2 | 871 | 3,266.21 |
20260107 | 3 | 2,711 | 10,063.36 | 3 | 1,811 | 6,909.36 |
20260108 | 4 | 4,091 | 15,043.56 | 1 | 1 | 3.76 |
20260109 | 1 | 1 | 3.64 | 3 | 1,941 | 7,152.84 |
20260112 | 1 | 1 | 3.68 | 3 | 1,881 | 7,082.18 |
20260113 | 2 | 1,991 | 7,267.22 | 3 | 949 | 3,541.20 |
20260114 | 4 | 4,061 | 14,770.64 | 1 | 1 | 3.74 |
20260115 | 1 | 1 | 3.62 | 3 | 1,981 | 7,221.02 |
20260116 | 1 | 1 | 3.64 | 4 | 3,771 | 13,941.24 |
20260119 | 4 | 4,151 | 15,089.66 | 3 | 1,821 | 6,874.46 |
20260120 | 4 | 3,951 | 14,564.30 | 1 | 1 | 3.70 |
20260121 | 3 | 2,481 | 9,085.50 | 1 | 1 | 3.70 |
20260122 | 1 | 1 | 3.79 | 5 | 6,071 | 23,288.19 |
20260123 | 3 | 2,521 | 9,660.60 | 5 | 5,521 | 22,070.20 |
20260126 | 4 | 3,841 | 15,378.82 | 2 | 891 | 3,688.72 |
20260127 | 3 | 2,441 | 9,671.28 | 1 | 1 | 3.98 |
20260128 | 2 | 1,751 | 6,846.45 | 2 | 224 | 893.72 |
20260129 | 4 | 3,531 | 13,678.17 | 2 | 366 | 1,460.32 |
20260130 | 3 | 2,251 | 8,535.84 | 1 | 1 | 3.84 |
20260202 | 1 | 1,600 | 6,032.00 | 2 | 1,061 | 4,084.78 |
20260203 | 2 | 1,561 | 5,963.08 | 3 | 2,171 | 8,499.88 |
20260204 | 3 | 2,171 | 8,210.75 | 1 | 1 | 3.85 |
20260205 | 4 | 3,221 | 11,908.74 | 1 | 1 | 3.74 |
20260206 | 4 | 3,071 | 11,200.58 | 1 | 1 | 3.68 |
20260209 | 3 | 1,921 | 6,957.99 | 1 | 1 | 3.69 |
20260210 | 1 | 1 | 3.67 | 4 | 4,821 | 17,847.67 |
20260211 | 4 | 3,071 | 11,169.88 | 1 | 1 | 3.68 |
20260212 | 1 | 1 | 3.55 | 2 | 1,181 | 4,251.55 |
20260213 | 3 | 1,991 | 7,092.01 | 1 | 1 | 3.61 |
20260216 | 5 | 4,406 | 15,279.94 | 1 | 1 | 3.59 |
20260217 | 1 | 1 | 3.43 | 2 | 1,251 | 4,365.93 |
20260218 | 3 | 1,851 | 6,376.19 | 1 | 1 | 3.49 |
20260219 | 4 | 2,721 | 9,257.88 | 1 | 1 | 3.48 |
20260220 | 4 | 2,581 | 8,678.29 | 1 | 1 | 3.39 |
20260223 | 5 | 3,697 | 12,071.27 | 3 | 2,701 | 9,237.73 |
20260224 | 4 | 2,411 | 7,986.25 | 1 | 1 | 3.35 |
20260225 | 3 | 1,521 | 4,920.08 | 1 | 1 | 3.28 |
20260226 | 1 | 1 | 3.27 | 3 | 2,841 | 9,347.27 |
20260227 | 1 | 1 | 3.34 | 4 | 5,441 | 18,496.64 |
20260302 | 6 | 5,511 | 17,690.22 | 1 | 1 | 3.22 |
20260303 | 6 | 4,901 | 15,838.37 | 1 | 1 | 3.37 |
20260304 | 1 | 1 | 3.16 | 5 | 8,471 | 27,722.36 |
20260305 | 2 | 501 | 1,628.33 | 3 | 2,661 | 8,888.13 |
20260306 | 2 | 1,351 | 4,336.79 | 3 | 2,611 | 8,616.59 |
20260309 | 4 | 2,831 | 9,178.97 | 2 | 1,261 | 4,224.27 |
20260310 | 1 | 1 | 3.34 | 6 | 9,651 | 32,795.94 |
20260311 | 4 | 3,241 | 10,929.88 | 1 | 1 | 3.48 |
20260312 | 2 | 1,491 | 4,965.10 | 2 | 1,191 | 4,061.30 |
20260313 | 4 | 3,091 | 10,199.83 | 1 | 1 | 3.33 |
20260316 | 3 | 1,961 | 6,323.71 | 3 | 1,650 | 5,469.48 |
20260317 | 1 | 1 | 3.27 | 3 | 2,561 | 8,579.67 |
20260318 | 3 | 1,991 | 6,619.47 | 1 | 1 | 3.37 |
20260319 | 4 | 2,971 | 9,633.40 | 1 | 1 | 3.30 |
20260320 | 2 | 1,391 | 4,381.70 | 2 | 1,291 | 4,169.90 |
20260323 | 4 | 2,911 | 8,935.88 | 4 | 2,779 | 8,930.84 |
20260324 | 4 | 2,881 | 8,995.93 | 2 | 1,291 | 4,169.93 |
20260325 | 2 | 1,371 | 4,250.16 | 1 | 1 | 3.16 |
20260326 | 5 | 4,311 | 12,983.99 | 1 | 1 | 3.09 |
20260327 | 1 | 1 | 3.25 | 11 | 23,201 | 76,137.55 |
20260330 | 1 | 1 | 3.97 | 10 | 15,501 | 61,966.67 |
20260331 | 5 | 6,751 | 24,540.66 | 1 | 1 | 3.66 |
20260401 | 3 | 2,671 | 9,701.24 | 4 | 3,771 | 14,224.24 |
20260402 | 3 | 2,691 | 9,800.85 | 1 | 1 | 3.65 |
20260403 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260406 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260407 | 1 | 1 | 3.70 | 1 | 1 | 3.70 |
20260408 | 1 | 1 | 3.61 | 6 | 7,201 | 26,219.81 |
20260409 | 3 | 2,931 | 10,498.91 | 1 | 1 | 3.61 |
20260410 | 1 | 1 | 3.57 | 2 | 911 | 3,288.67 |
20260413 | 4 | 4,351 | 15,391.96 | 1 | 1 | 3.56 |
20260414 | 2 | 954 | 3,377.22 | 5 | 5,701 | 21,042.10 |
20260415 | 1 | 1 | 3.76 | 5 | 5,301 | 20,414.16 |
20260416 | 3 | 2,921 | 11,105.66 | 2 | 821 | 3,193.66 |
20260417 | 1 | 1 | 3.81 | 5 | 5,031 | 19,675.91 |
20260420 | 4 | 4,551 | 17,398.14 | 1 | 1 | 3.84 |
20260421 | 4 | 4,411 | 16,463.56 | 1 | 1 | 3.76 |
20260422 | 3 | 2,781 | 10,211.94 | 1 | 1 | 3.74 |
20260423 | 2 | 1,981 | 7,191.04 | 1 | 1 | 3.64 |
20260424 | 4 | 4,011 | 14,348.32 | 1 | 1 | 3.62 |
20260427 | 3 | 2,318 | 8,214.59 | 1 | 1 | 3.55 |
20260428 | 3 | 2,421 | 8,551.15 | 2 | 1,061 | 3,840.75 |
20260429 | 3 | 2,411 | 8,401.70 | 2 | 1,081 | 3,891.60 |
20260430 | 3 | 2,381 | 8,201.90 | 1 | 1 | 3.50 |
20260501 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260504 | 3 | 2,311 | 7,868.36 | 2 | 1,131 | 3,947.16 |
20260505 | 3 | 2,291 | 7,708.49 | 3 | 2,311 | 7,996.29 |
20260506 | 1 | 1 | 3.42 | 5 | 6,801 | 23,821.12 |
20260507 | 1 | 1 | 3.59 | 5 | 6,281 | 22,994.29 |
20260508 | 3 | 2,701 | 9,621.00 | 2 | 961 | 3,507.60 |
20260511 | 1 | 1 | 3.57 | 4 | 3,941 | 14,254.37 |
20260512 | 3 | 2,781 | 9,933.83 | 3 | 1,901 | 6,986.43 |
20260513 | 1 | 1 | 3.68 | 4 | 3,751 | 14,017.48 |
20260514 | 1 | 1 | 3.71 | 3 | 1,811 | 6,746.41 |
20260515 | 3 | 2,911 | 10,660.27 | 1 | 1 | 3.67 |
20260518 | 4 | 4,411 | 15,514.43 | 1 | 1 | 3.63 |
20260519 | 1 | 1 | 3.50 | 1 | 1 | 3.50 |
20260520 | 3 | 2,751 | 9,606.66 | 1 | 1 | 3.56 |
20260521 | 4 | 4,011 | 13,947.22 | 1 | 1 | 3.52 |
20260522 | 4 | 3,911 | 13,111.16 | 3 | 2,151 | 7,464.26 |
20260525 | 1 | 1 | 3.37 | 4 | 4,321 | 14,905.17 |
20260526 | 2 | 914 | 3,116.80 | 2 | 1,031 | 3,598.17 |
20260527 | 11 | 17,411 | 53,176.77 | 1 | 1 | 3.07 |
20260528 | 6 | 7,131 | 21,135.56 | 1 | 1 | 3.06 |
20260529 | 3 | 2,111 | 6,005.20 | 1 | 1 | 2.90 |
20260601 | 3 | 2,041 | 5,765.23 | 2 | 1,401 | 4,048.83 |
20260602 | 4 | 2,390 | 6,659.66 | 1 | 1 | 2.80 |
20260603 | 3 | 1,961 | 5,407.18 | 1 | 1 | 2.78 |
20260604 | 4 | 2,881 | 7,839.44 | 1 | 1 | 2.74 |
20260605 | 1 | 1 | 2.72 | 4 | 6,011 | 16,557.92 |
20260608 | 3 | 2,041 | 5,546.13 | 1 | 1 | 2.73 |
20260609 | 3 | 1,971 | 5,296.83 | 2 | 1,461 | 4,017.73 |
20260610 | 3 | 1,961 | 5,250.31 | 1 | 1 | 2.71 |
20260611 | 1 | 1 | 2.66 | 2 | 1,491 | 4,010.76 |
20260612 | 1 | 1 | 2.72 | 3 | 2,961 | 8,068.92 |
20260615 | 3 | 2,061 | 5,538.66 | 2 | 1,421 | 3,914.86 |
20260616 | 5 | 4,901 | 12,736.29 | 1 | 1 | 2.69 |
20260617 | 1 | 1 | 2.56 | 3 | 1,511 | 3,868.36 |
20260618 | 10 | 10,945 | 25,700.63 | 1 | 1 | 2.37 |
20260619 | 4 | 2,791 | 6,152.77 | 1 | 1 | 2.27 |
20260622 | 1 | 1 | 2.22 | 1 | 1 | 2.22 |
20260623 | 2 | 1,041 | 2,290.23 | 1 | 1 | 2.23 |
20260624 | 4 | 2,571 | 5,642.25 | 1 | 1 | 2.25 |
20260625 | 6 | 3,842 | 8,014.42 | 1 | 1 | 2.09 |
20260626 | 4 | 2,351 | 4,783.08 | 1 | 1 | 2.08 |
20260629 | 2 | 1,081 | 2,172.85 | 2 | 1,801 | 3,728.05 |
20260630 | 2 | 29 | 58.88 | 5 | 10,571 | 22,546.84 |
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious diseases for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biopharmaceuticals and next-generation HDL vectors that target the immune-inflammatory dysregulation at the heart of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706842658/en/
Contacts:
ABIONYX Pharma
infos@abionyx.com
